# A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

> **NCT03467373** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 111 (actual)

## Conditions studied

- B-Cell Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Obinutuzumab (G)
- **DRUG:** Rituximab (R)
- **DRUG:** Tocilizumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Polatuzumab vedotin

## Key facts

- **NCT ID:** NCT03467373
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-13
- **Primary completion:** 2024-12-02
- **Final completion:** 2024-12-02
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03467373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03467373, "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03467373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*